Who are HLX04-O's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): HLX04.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hlx04-o.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

HLX04-O — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HLX04-O (HLX04-O) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor (monoclonal antibody / bevacizumab biosimilar). Area: Oncology.

phase 3 VEGF inhibitor (monoclonal antibody / bevacizumab biosimilar) VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HLX04-O (HLX04-O) — Shanghai Henlius Biotech. HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HLX04-O TARGET	HLX04-O	Shanghai Henlius Biotech	phase 3	VEGF inhibitor (monoclonal antibody / bevacizumab biosimilar)	VEGF (Vascular Endothelial Growth Factor)
HLX04	HLX04	Shanghai Henlius Biotech	phase 3	VEGF inhibitor (monoclonal antibody / bevacizumab biosimilar)	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor (monoclonal antibody / bevacizumab biosimilar) class)

Shanghai Henlius Biotech · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HLX04-O — Competitive Intelligence Brief. https://druglandscape.com/ci/hlx04-o. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing